Evidence map›Paper›PMID 28272393›Full record

ArticleMucosal immunology2017

Experimental vaccine induces Th1-driven immune responses and resistance to Neisseria gonorrhoeae infection in a murine model.

Y Liu, L A Hammer, W Liu, M M Hobbs, R A Zielke, A E Sikora, A E Jerse, N K Egilmez, M W Russell

Open access · bronzeAbstract read
In one paragraph

Article in Mucosal immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 112 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Protection againstFrontiers in immunology · 2025
    Article
  20. PreclinicalFrontiers in immunology · 2025
    Article

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Y LiuTherapyX Inc., Buffalo, New York, USA.
L A HammerTherapyX Inc., Buffalo, New York, USA.
W LiuDepartment of Pediatrics, Digestive Diseases and Nutrition Center, University at Buffalo, Buffalo, New York, USA.
M M HobbsDepartment of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.
R A ZielkeDepartment of Pharmaceutical Sciences, Oregon State University, Corvallis, Oregon, USA.
A E SikoraDepartment of Pharmaceutical Sciences, Oregon State University, Corvallis, Oregon, USA.
A E JerseDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
N K EgilmezDepartment of Microbiology and Immunology, University of Louisville, Louisville, Kentucky, USA.
M W RussellDepartment of Microbiology and Immunology, University at Buffalo, Buffalo, New York, USA.
University at Buffalo, State University of New York · USOregon State University · USUniformed Services University of the Health Sciences · USUniversity of Louisville · USUniversity of North Carolina at Chapel Hill · US

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Marian Esvelt · 1985 to 2026
$296.4M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Proteomics-Driven Reverse Vaccinology for GonorrheaR01AI117235 · NIAID · OREGON STATE UNIVERSITY · PI Aleksandra Elzbieta Sikora · 2015 to 2026
$6.7M
Therapy and Prophylaxis for Genital Tract InfectionR43AI104067 · NIAID · THERAPYX, INC. · PI LIU, YINGRU · 2013 to 2013
$300k
Experimental Gonococcal VaccineR43AI115877 · NIAID · THERAPYX, INC. · PI LIU, YINGRU · 2015 to 2015
$271k
NCI NIH HHS P30 CA015704NIAID NIH HHS P30 AI050410NIAID NIH HHS R01 AI117235NIAID NIH HHS R43 AI104067NIAID NIH HHS R43 AI115877
6 · The paper itself

Abstract

Female mice were immunized intravaginally with gonococcal outer membrane vesicles (OMVs) plus microencapsulated interleukin-12 (IL-12), and challenged using an established model of genital infection with Neisseria gonorrhoeae. Whereas sham-immunized and control animals cleared the infection in 10-13 days, those immunized with OMV plus IL-12 cleared infection with homologous gonococcal strains in 6-9 days. Significant protection was also seen after challenge with antigenically distinct strains of N. gonorrhoeae, and protective anamnestic immunity persisted for at least 6 months after immunization. Serum and vaginal immunoglobulin G (IgG) and IgA antibodies were generated against antigens expressed by homologous and heterologous strains. Iliac lymph node CD4

Indexed as

AnimalsAntibodies, ViralBacterial LoadBacterial VaccinesCells, CulturedDisease Models, AnimalExtracellular VesiclesFemaleGonorrheaHumansImmunizationInterferon-gammaInterleukin-12Lymphocyte ActivationMiceMice, Inbred BALB CAntibodies, ViralBacterial VaccinesInterferon-gammaInterleukin-12Peptide Elongation Factor Tuporin protein, NeisseriaPorins

Identifiers

PMID28272393
PMCPMC5591041
OpenAlexW2591811698

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.